PNC Financial Services Group Inc. (The) Common Stock vs Viatris Inc — how do they compare? PNC Financial Services Group Inc. (The) Common Stock trades at $219.44 (market cap $87.64B), while Viatris Inc trades at $17.71 (market cap $20.03B). The key difference: PNC Financial Services Group Inc. (The) Common Stock is far larger — about 4.4× Viatris Inc's market cap, and PNC Financial Services Group Inc. (The) Common Stock pays the higher dividend (3.64%). Which is the better fit depends on your goals.
| PNC | VTRS | |
|---|---|---|
Market Cap | $87.64B | $20.03B |
Volume | 1,687,662 | 14,109,977 |
Sector | Financials | Health |
52-Week High | $256.97 | $18.27 |
52-Week Low | $178.37 | $9.74 |
Enterprise Value | $144.63B | $32.15B |
Dividend Yield | 3.64% | 2.75% |
Typical Hold Time | — | 57 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.
The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
PNC Financial Services Group is a financial services holding company. Its businesses include retail banking, corporate and institutional banking, and asset management.
Read more on PNC →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →